Delian Asparouhov of Founders Fund recently reviewed his genetic data from Nucleus Genomics, revealing predispositions to various conditions. Nucleus is pioneering potential advancements in personalized healthcare, perceiving a future where genetic testing is commonplace, influencing medical treatments and family planning. With a $14 million Series A funding, led by significant investors, the startup emerges as a leader in accessible genetic testing, now available for $400, with vast potential for widespread use and an ever-expanding list of conditions assessed.
"DNA is actually the kind of ultimate health test," Sadeghi said. "So one swab and you get your analysis on about 800 plus conditions."
Asparouhov's reaction seems nonchalant, it's only because he and the Nucleus team he backed are dreaming much, much bigger."
Nucleus, staffed by a team of PhDs and genetic experts, charges $400 to send a saliva sample to a third party sequencer and then analyze the results.
Sadeghi believes that, in the next five years, 'the cost of sequencing the human genome will continue to plummet.'
Collection
[
|
...
]